Comparing dopamine agonists in Parkinson's disease

Current Opinion in Neurology

Volumn 16, Issue SUPPL. 1, 2003, Pages

  Bonuccelli, Ubaldo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Comparison; Dopamine agonists; Parkinson's disease

Indexed keywords

ANTIEMETIC AGENT; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; DRUG EFFICACY; DYSKINESIA; HALLUCINATION; HUMAN; MOTOR DYSFUNCTION; NAUSEA; PARKINSON DISEASE; SIDE EFFECT; SOMNOLENCE;

EID: 1542327566     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200312001-00004     Document Type: Conference Paper

References (52)

1. Tan E-K, Jankovic J. Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol 2002; 24:247-253.
2. LeWitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983; 33:1009-1014.
3. Goetz CG, Tanner CM, Glantz RH, et al. Chronic agonist therapy for Parkinson's disease. Neurology 1985; 35:749-751.
4. Goetz CG, Shannon KM, Tanner CM, et al. Agonist substitution in advanced Parkinson's disease. Neurology 1989; 39:1121-1122.
5. Pezzoli G, Martignoni E, Pacchetti V, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994; 9:431-436.
6. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995; 45 (Suppl 3):S13-S21.
7. Boas J, Worm-Peterson J, Dupont E, et al. The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine in an open-label crossover study. Eur J Neurol 1996; 3:44-49.
8. Clarke CE, Speller JM. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease. Cochrane Database. Syst Rev 2000; 2:CD000235.
9. Bonnet AM, Serre I, Marconi R, et al. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Mov Disord 1995; 10:668-671.
10. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997; 49:1060-1065.
11. Clarke CE, Speller JM, Clarke JA. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database. Syst Rev 2000; 3:CD002259.
12. Brunt ER, Brooks DJ, Korczyn AD, et al. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm 2002; 109:489-502.
13. Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomised trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology 1999; 53:364-370.
14. Canesi M, Antonini A, Mariani CB, et al. An overnight switch to ropinirole therapy in patients with Parkinson's disease [short communication]. J Neural Transm 1999; 106:925-929.
15. Clarke CE, Deane KHO. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database. Syst Rev 2001; 2:CD001517.
16. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996; 47:785-788.
17. Clarke CE, Deane KHO. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database. Syst Rev 2001; 1:CD001519.
18. Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow? Neurology 1999; 52:1227-1229.
19. Hanna PA, Ratkos L, Ondo WG, Jankovic J. Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm 2001; 108:63-70.
20. Ulm G, Schuler P, for the MODAC Study Group. Cabergoline versus Pergolide: a video-blinded, randomized, multicenter cross-over study [in German]. Akt Neurologie 1999; 25:360-365.
21. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994; 9:40-47.
22. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996; 19:202-212.
23. Hutton JT, Koller WC, Ahlskog JE, et al. Multicentre, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996; 46:1062-1065.
24. Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996; 19:234-245.
25. Steiger MJ, El-Debas T, Findley L, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996; 243:68-72.
26. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49:162-168.
27. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998; 51:1057-1062.
28. Wermuth L and The Danish Pramipexole Study Group. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. Eur J Neurol 1998; 5:235-242.
29. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatr 1999; 66:436-441.
30. Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 1999; 14:725-730.
31. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18:338-347.
32. Shannon KM, Bennett JP, Friedman JH for the Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997; 49:724-728.
33. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997; 49:393-399.
34. Brooks DJ, Abbott RJ, Lees AJ, et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 1998; 21:101-107.
35. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early Parkinson's disease. A randomized controlled study. Neurology 1999; 53:573-599.
36. Parkinson Study Group. Pramipexole vs levodopa as initial treatment of Parkinson's disease: a randomised controlled trial. JAMA 2000; 284:1931-1938.
37. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342:1484-1491.
38. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998; 55:23-30.
39. Oertel WH, Schwarz J, Leenders KL, et al, on behalf of the Pelmopet-Study Group. Results of a 3 year randomized, double-blind, PET-controlled study of Pergolide vs. L-dopa as Monotherapy in Early Parkinson's Disease (PEL-MOPET-trial). J Neurol Sci 2001; 187 (Suppl 1):S444 [abstract].
40. Frucht SJ, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52:1908-1910.
41. Ferreira JJ, Galitzky M, Rascol O. Sleep attacks and Parkinson's disease treatment. Lancet 2000; 355:1333-1334.
42. Hauser RA, Gauger L, McDowell Anderson W, Zesicwicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 2000; 15:658-663.
43. Pirker W, Happe S. Sleep attacks in Parkinson's disease [letter]. Lancet 2000; 356:597-598.
44. Tracik F, Ebersbach G. Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings. Mov Disord 2001; 16:500-506.
45. Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 2002; 324:1483-1487.
46. Ulivelli M, Rossi S, Lombardi C, et al. Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD. Neurology 2002; 58:462-465.
47. Schapira AH. Sleep attacks (sleep episodes) with pergolide. Lancet 2000; 355:1332-1333.
48. Hobson DE, Lang AE, Martin WR, et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson's disease. A survey by the Canadian Movement Disorders Group. JAMA 2002; 287:455-463.
49. Frucht SJ, Greene PE, Fahn S. Sleep episodes in Parkinson's disease: a wake-up call. Mov Disord 2000; 15:601-603.
50. Cantor CR, Stern MB. Dopamine agonists and sleep in Parkinson's disease. Neurology 2002; 58 (Suppl 1):S71-S78.
51. Paus S, Brecht HM, Koster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003; 18:659-667.
52. Muller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin Neuropharmacol 2003; 3:109-111.